Alzamend Neuro, Inc.
ALZN · NASDAQ
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Market Cap | $8,554 | $4,739 | $4,626 | $56,615 |
| - Cash | $4,449 | $5,621 | $3,949 | $3,358 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $4,104 | -$882 | $677 | $53,257 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$28 | -$13 | -$13 |
| % Margin | – | – | – | – |
| EBITDA | -$998 | -$2,700 | -$1,126 | -$1,025 |
| % Margin | – | – | – | – |
| Net Income | -$1,001 | -$2,703 | -$1,139 | -$1,039 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.3 | -1.28 | -2.22 | -0.19 |
| % Growth | 76.6% | 42.3% | -1,068.4% | – |
| Operating Cash Flow | -$1,171 | -$2,363 | -$689 | -$1,424 |
| Capital Expenditures | $0 | $0 | -$210 | $0 |
| Free Cash Flow | -$1,171 | -$2,363 | -$899 | -$1,424 |